Last reviewed · How we verify
Atropine Sulfate Ophthalmic Solution
At a glance
| Generic name | Atropine Sulfate Ophthalmic Solution |
|---|---|
| Sponsor | Biomedical Advanced Research and Development Authority |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens Wear
- Effects of Auricular Point Pressing With Pellets in Children With Insufficient Hyperopia Reserve (NA)
- The Effect of 0.01% Atropine Eye Drops on Axial Length and Refraction in Myopic Children Compared to a Control Group (PHASE2)
- PROTECT-Study: Prospective Research on Optimizing Atropine Concentration Escalation for Children's Myopia Prevention (PHASE1, PHASE2)
- A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control (PHASE3)
- Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine (NA)
- APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes (PHASE4)
- Low Concentration Atropine Combined With Soft Contact Lens in Controlling Myopia Progression in Children With High Myopia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: